Product Name: GSK3b (14-33)
Product Number: PE-01BDB85
Size: 200 µg      Price:48.00
1 mg      $US96.00
5 mg      208.00
Peptide Name: GSK3b (14-33)

Product Use: Services as a blocking peptide for use with the GSK3b-ANT rabbit polyclonal antibody (Cat. No.: AB-NK270-3) that is also available from Kinexus. The peptide sequence is located near N-terminus.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: CKPVQQPSAFGSMKVSRDKD

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: Amide

Peptide Molecular Mass Calculated: 2207.5 Da

Peptide Purity Percent after Synthesis and Purification: >80

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: GSK3b pan-specific antibody (Cat. No.: AB-NK270-3)

Scientific Background: GSK3b is a protein-serine/threonine kinase of the CMGC group and GSK family. It is a critical enzyme in glycogen metabolism, and plays a role in pathological conditions such as cancer, diabetes, and neurological diseases. This kinase is highly expressed and widely distributed in most tested human tissues. Orthologues of GSK3b are amongst the most highly conserved protein kinases in animals, plants, fungi and unicellular eukaryotes. GSK3b is activated by phosphorylation at Y216 by MEK1 and MEK2, and inhibited by phosphorylation of S9. GSK3b phosphorylates and inhibits glycogen synthase. It is implicated in the regulation of several physiological processes, including control of glycogen and protein synthesis by insulin, and modulation of the transcription factors AP-1 and CREB. Transient transfection of human GSK3b into Chinese hamster ovary cells stably transfected with individual human tau isoforms leads to hyperphosphorylation of tau. GSK3b has been linked with the development of Alzheimer’s disease, bipolar disorder, and Type 2 diabetes. Mutations leading to upregulation of GSK3b are also implicated in ovarian, prostate, pancreatic, colorectal, neuroblastoma, and glioblastoma neoplasms, by positively regulating cyclin D1 and thus promoting cell cycle progression.